Linfoma cutáneo de células grandes B de las piernas

Willenze, 2003, Classification of primary cutaneous lymphomas, Haematologica, 88, 6 Vermeer, 1996, Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group, Arch Dermatol, 132, 1304, 10.1001/archderm.1996.03890350042008 Goodlad, 2003, Primary cutaneous diffuse large B-cell lymphoma. Prognostic significance of clinicopathological subtypes, Am J Surg Pathol, 27, 1538, 10.1097/00000478-200312000-00006 Hermine, 1996, Prognostic significance of bcl-2 protein expresion in aggressive non-Hodgkin's lymphoma, Blood, 87, 265, 10.1182/blood.V87.1.265.265 Hill, 1996, Prognostic significance of bcl-2 expression and bcl-2 major break point region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British National Lymphoma Investigation study, Blood, 88, 1046, 10.1182/blood.V88.3.1046.1046 Kramer, 1996, Clinical significance of bcl-2 and p53 protein expression in diffuse large B-cell lymphoma: A population-based study, J Clin Oncol, 14, 2131, 10.1200/JCO.1996.14.7.2131 Grange, 2004, Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas, Blood, 103, 1662, 10.1182/blood-2003-08-2726 Wechsler, 2000, Primary cutaneous large B-cell lymphomas, Semin Cutan Med Surg, 19, 130, 10.1016/S1085-5629(00)80010-3 Child, 2001, Absence of the t(14;18) chromosomal translocation in primary cutaneous B-cell lymphoma, Br J Dermatol, 144, 735, 10.1046/j.1365-2133.2001.04128.x Cantonetti, 2003, Rituximab therapy for primary cutaneous B-cell lymphomas, Haematologica, 88, 75 Anderson, 1984, Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation, Blood, 63, 1424, 10.1182/blood.V63.6.1424.1424 Heinzerling, 2000, Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma, Arch Dermatol, 136, 374, 10.1001/archderm.136.3.374 Sabroe, 2000, Rituximab in cutaneous B-cell lymphoma: a report of two cases, Br J Dermatol, 143, 157, 10.1046/j.1365-2133.2000.03607.x McLaughlin, 1998, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a fourdose treatment program, J Clin Oncol, 16, 2825, 10.1200/JCO.1998.16.8.2825 Winkler, 1999, Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8), Blood, 94, 2217, 10.1182/blood.V94.7.2217.419k02_2217_2224 Heinzerling, 2000, Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma, Cancer, 89, 1835, 10.1002/1097-0142(20001015)89:8<1835::AID-CNCR26>3.0.CO;2-H Aboulafia, 2001, Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab), Am J Clin Oncol, 24, 237, 10.1097/00000421-200106000-00005 Bonnekoh, 2002, Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monot erapy with the CD20-antibody rituximab, J Cancer Res Clin Oncol, 128, 161, 10.1007/s00432-001-0313-2 Massengale, 2002, CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy, J Am Acad Dermatol, 46, 441, 10.1067/mjd.2002.108490 Looney, 2005, Treatment of SLE with anti-CD20 monoclonal antibody, Curr Dir Autoimmun, 8, 193, 10.1159/000082104 Morrison, 2004, Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab), J Am Acad Dermatol, 51, 817, 10.1016/j.jaad.2004.06.007